相关实验视频
Updated: Jan 17, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
906
肥胖的药物治疗:最近的更新
Thomas Ward Fredrick1, Michael Camilleri1, Andres Acosta1
1Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, 55905, USA.
Clinical pharmacology : advances and applications
|September 25, 2025
概括
这篇评论详细介绍了最新的抗肥胖药物,包括FDA批准的药物和正在开发的药物. 它涵盖了体重管理疗法的机制,有效性和未来目标.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 肥胖是一种复杂的代谢疾病,对健康有重大影响.
- 了解饥饿和腹的生理学对于开发有效的抗肥胖药物至关重要.
- 目前的药物疗法针对参与食欲调节的各种途径.
研究的目的:
- 提供当前和新兴抗肥胖药物的全面概述.
- 详细介绍这些药理学剂的作用机制,疗效和益处.
- 讨论将这些药物纳入肥胖治疗计划的最佳实践.
主要方法:
- 截至2025年2月,对抗肥胖药物的最新更新进行叙述性审查.
- 专注于FDA批准的药物,并选择2期和3期试验中的药物.
- 对生理机制,疗效和比较数据的分析.
主要成果:
- 对治疗遗传性肥胖症的非类药物 (orlistat,phentermine,phentermine-topiramate,naltrexone-bupropion) 和setmelanotide进行审查.
- 详细检查GLP-1受体激动剂 (利拉格卢提德,塞马格卢提德) 和双GIP/GLP-1激动剂 (蒂尔泽帕提德).
- 探索包括双/三重激动剂和氨酸激动剂在内的管道内cretin目标.
结论:
- 针对肥胖的药理干预正在迅速发展,具有多种不同的作用机制.
- 新兴的疗法,特别是以基为基础的疗法,在体重管理方面显示出显著的前景.
- 优化治疗需要了解药物疗效,辅助疗法和监测策略.
相关概念视频
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
247
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
247
Drug Dosing: Obese Patients
225
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169
Drug Therapy
245
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
245
Atherosclerosis III: Management
321
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
321
Diabetes: Management and Pharmacotherapy
868
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
868

